176 related articles for article (PubMed ID: 11137181)
1. Effect of octreotide on insulin requirement, hepatic glucose production, growth hormone, glucagon and c-peptide levels in type 2 diabetic patients with chronic renal failure or normal renal function.
Di Mauro M; Papalia G; Le Moli R; Nativo B; Nicoletti F; Lunetta M
Diabetes Res Clin Pract; 2001 Jan; 51(1):45-50. PubMed ID: 11137181
[TBL] [Abstract][Full Text] [Related]
2. Effects of octreotide on glycaemic control, glucose disposal, hepatic glucose production and counterregulatory hormones secretion in type 1 and type 2 insulin treated diabetic patients.
Lunetta M; Di Mauro M; Le Moli R; Nicoletti F
Diabetes Res Clin Pract; 1997 Nov; 38(2):81-9. PubMed ID: 9483371
[TBL] [Abstract][Full Text] [Related]
3. Combination of continuous subcutaneous infusion of insulin and octreotide in Type 1 diabetic patients.
Bruttomesso D; Fongher C; Silvestri B; Barberio S; Marescotti MC; Iori E; Valerio A; Crazzolara D; Pianta A; Tiengo A; Del Prato S
Diabetes Res Clin Pract; 2001 Feb; 51(2):97-105. PubMed ID: 11165689
[TBL] [Abstract][Full Text] [Related]
4. Insulin secretion, insulin action, and hepatic glucose production in identical twins discordant for non-insulin-dependent diabetes mellitus.
Vaag A; Henriksen JE; Madsbad S; Holm N; Beck-Nielsen H
J Clin Invest; 1995 Feb; 95(2):690-8. PubMed ID: 7860750
[TBL] [Abstract][Full Text] [Related]
5. Lack of pharmacological effect of subcutaneous octreotide in an insulin-dependent diabetic patient: reversal after mixing with aprotinin.
Lunetta M; Di Mauro M; Le Moli R
J Endocrinol Invest; 1997 Jun; 20(6):331-4. PubMed ID: 9294779
[TBL] [Abstract][Full Text] [Related]
6. Assessment of hepatic insulin action in obese type 2 diabetic patients.
Staehr P; Hother-Nielsen O; Levin K; Holst JJ; Beck-Nielsen H
Diabetes; 2001 Jun; 50(6):1363-70. PubMed ID: 11375337
[TBL] [Abstract][Full Text] [Related]
7. Antidiabetogenic effect of glucagon-like peptide-1 (7-36)amide in normal subjects and patients with diabetes mellitus.
Gutniak M; Orskov C; Holst JJ; Ahrén B; Efendic S
N Engl J Med; 1992 May; 326(20):1316-22. PubMed ID: 1348845
[TBL] [Abstract][Full Text] [Related]
8. Normal glucose-induced suppression of glucose production but impaired stimulation of glucose disposal in type 2 diabetes: evidence for a concentration-dependent defect in uptake.
Nielsen MF; Basu R; Wise S; Caumo A; Cobelli C; Rizza RA
Diabetes; 1998 Nov; 47(11):1735-47. PubMed ID: 9792543
[TBL] [Abstract][Full Text] [Related]
9. Different effects of octreotide by continuous night infusion at increasing rate or by evening injections at different times on morning hyperglycemia and growth hormone levels in insulin-dependent diabetic patients.
Lunetta M; Di Mauro M; Le Moli R
J Endocrinol Invest; 1998; 21(7):454-8. PubMed ID: 9766261
[TBL] [Abstract][Full Text] [Related]
10. Resistance to insulin's acute direct hepatic effect in suppressing steady-state glucose production in individuals with type 2 diabetes.
Lewis GF; Carpentier A; Vranic M; Giacca A
Diabetes; 1999 Mar; 48(3):570-6. PubMed ID: 10078558
[TBL] [Abstract][Full Text] [Related]
11. Effect of glucagon-like peptide 1(7-36) amide on glucose effectiveness and insulin action in people with type 2 diabetes.
Vella A; Shah P; Basu R; Basu A; Holst JJ; Rizza RA
Diabetes; 2000 Apr; 49(4):611-7. PubMed ID: 10871199
[TBL] [Abstract][Full Text] [Related]
12. Effect of glyburide on glycemic control, insulin requirement, and glucose metabolism in insulin-treated diabetic patients.
Simonson DC; Delprato S; Castellino P; Groop L; DeFronzo RA
Diabetes; 1987 Feb; 36(2):136-46. PubMed ID: 3100365
[TBL] [Abstract][Full Text] [Related]
13. Glucagonostatic actions and reduction of fasting hyperglycemia by exogenous glucagon-like peptide I(7-36) amide in type I diabetic patients.
Creutzfeldt WO; Kleine N; Willms B; Orskov C; Holst JJ; Nauck MA
Diabetes Care; 1996 Jun; 19(6):580-6. PubMed ID: 8725855
[TBL] [Abstract][Full Text] [Related]
14. Hepatic glucose production is regulated both by direct hepatic and extrahepatic effects of insulin in humans.
Lewis GF; Zinman B; Groenewoud Y; Vranic M; Giacca A
Diabetes; 1996 Apr; 45(4):454-62. PubMed ID: 8603767
[TBL] [Abstract][Full Text] [Related]
15. Decreased hepatic glucagon responses in type 1 (insulin-dependent) diabetes mellitus.
Orskov L; Alberti KG; Mengel A; Møller N; Pedersen O; Rasmussen O; Seefeldt T; Schmitz O
Diabetologia; 1991 Jul; 34(7):521-6. PubMed ID: 1916058
[TBL] [Abstract][Full Text] [Related]
16. Effect of loss of first-phase insulin secretion on hepatic glucose production and tissue glucose disposal in humans.
Luzi L; DeFronzo RA
Am J Physiol; 1989 Aug; 257(2 Pt 1):E241-6. PubMed ID: 2669517
[TBL] [Abstract][Full Text] [Related]
17. Octreotide: a long-acting inhibitor of endogenous hormone secretion for human metabolic investigations.
Krentz AJ; Boyle PJ; Macdonald LM; Schade DS
Metabolism; 1994 Jan; 43(1):24-31. PubMed ID: 8289671
[TBL] [Abstract][Full Text] [Related]
18. Glucose-mediated glucose disposal in insulin-resistant normoglycemic relatives of type 2 diabetic patients.
Henriksen JE; Levin K; Thye-Rønn P; Alford F; Hother-Nielsen O; Holst JJ; Beck-Nielsen H
Diabetes; 2000 Jul; 49(7):1209-18. PubMed ID: 10909980
[TBL] [Abstract][Full Text] [Related]
19. Metabolic effects of successful intraportal islet transplantation in insulin-dependent diabetes mellitus.
Luzi L; Hering BJ; Socci C; Raptis G; Battezzati A; Terruzzi I; Falqui L; Brandhorst H; Brandhorst D; Regalia E; Brambilla E; Secchi A; Perseghin G; Maffi P; Bianchi E; Mazzaferro V; Gennari L; Di Carlo V; Federlin K; Pozza G; Bretzel RG
J Clin Invest; 1996 Jun; 97(11):2611-8. PubMed ID: 8647955
[TBL] [Abstract][Full Text] [Related]
20. Type 2 diabetic patients have increased gluconeogenic efficiency to substrate availability, but intact autoregulation of endogenous glucose production.
Toft I; Jenssen T
Scand J Clin Lab Invest; 2005; 65(4):307-20. PubMed ID: 16076686
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
